{"id":27090,"date":"2019-07-01T17:08:14","date_gmt":"2019-07-01T15:08:14","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=27090"},"modified":"2022-03-09T11:22:36","modified_gmt":"2022-03-09T10:22:36","slug":"01-juli-2019-dermapharm-holding-se-with-increased-free-float","status":"publish","type":"post","link":"https:\/\/dev.cometis.de\/en\/01-juli-2019-dermapharm-holding-se-with-increased-free-float\/","title":{"rendered":"01. Juli 2019<\/span> | Dermapharm Holding SE with increased free float"},"content":{"rendered":"

[et_pb_section admin_label=”section”][et_pb_row admin_label=”Zeile” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” use_custom_gutter=”off” custom_padding=”||0px|” padding_mobile=”off” allow_player_pause=”off” parallax=”off” parallax_method=”off” make_equal=”off” parallax_1=”off” parallax_method_1=”off” parallax_2=”off” parallax_method_2=”off” column_padding_mobile=”on”][et_pb_column type=”1_2″][et_pb_text admin_label=”Schaltfl\u00e4che %22zur\u00fcck zum Archiv%22″ background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Corporate news<\/h1>\n

to the archive<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″][et_pb_image admin_label=”Logo” src=”https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei%C3%9F_2-7.png” show_in_lightbox=”off” url_new_window=”off” use_overlay=”off” animation=”off” sticky=”off” align=”right” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

[\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” saved_tabs=”all”]<\/p>\n

Dermapharm Holding SE with increased free float<\/h1>\n

Gr\u00fcnwald, July 1, 2019 \u2013 Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded drugs for selected therapeutic areas in Germany with a growing international presence, has been informed by Themis Beteiligungs-Aktiengesellschaft (“Themis”) that on June 28, 2019 580,000 shares of Dermapharm for the price of 30.00 Euros per share have been sold outside a trading venue.<\/strong><\/p>\n

The 580,000 shares are from the agreed Greenshoe option. Themis had acquired these shares after the flotation on February 9, 2018 to stabilize the price.<\/p>\n

Following the sale, the shareholder structure is now composed as follows: At 75.05% (previously 76.13%), the majority of the no-par shares continue to be held by Themis. 24.95% (previously 23.87%) of the shares of Dermapharm are in free float.<\/p>\n

For the time being Dermapharm expects that Themis will not further reduce its share in Dermapharm.<\/p>\n

[\/et_pb_text][et_pb_text admin_label=”Schaltfl\u00e4che %22Post as PDF%22″ background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Post as PDF<\/a><\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Gr\u00fcnwald, July 1, 2019 \u2013 Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded drugs for selected therapeutic areas in Germany with a growing international presence, has been informed by Themis Beteiligungs-Aktiengesellschaft (“Themis”) that on June 28, 2019 580,000 shares of Dermapharm for the price of 30.00 Euros per share have been sold outside a trading venue.<\/p>\n","protected":false},"author":24813,"featured_media":54374,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[326,448],"tags":[481],"class_list":["post-27090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news-en","category-news-en","tag-481"],"acf":[],"yoast_head":"\n01. Juli 2019 | Dermapharm Holding SE with increased free float - cometis AG<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"01. Juli 2019 | Dermapharm Holding SE with increased free float - cometis AG\" \/>\n<meta property=\"og:description\" content=\"Gr\u00fcnwald, July 1, 2019 \u2013 Dermapharm Holding SE ("Dermapharm"), a leading manufacturer of patent-free branded drugs for selected therapeutic areas in Germany with a growing international presence, has been informed by Themis Beteiligungs-Aktiengesellschaft ("Themis") that on June 28, 2019 580,000 shares of Dermapharm for the price of 30.00 Euros per share have been sold outside a trading venue.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-01T15:08:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-09T10:22:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\" \/>\n\t<meta property=\"og:image:width\" content=\"172\" \/>\n\t<meta property=\"og:image:height\" content=\"174\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/0f6ec71e9167dd48a24950f3cc6b2003\"},\"headline\":\"01. Juli 2019 | Dermapharm Holding SE with increased free float\",\"datePublished\":\"2019-07-01T15:08:14+00:00\",\"dateModified\":\"2022-03-09T10:22:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\"},\"wordCount\":387,\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"keywords\":[\"2019\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\",\"url\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\",\"name\":\"01. Juli 2019 | Dermapharm Holding SE with increased free float - cometis AG\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"datePublished\":\"2019-07-01T15:08:14+00:00\",\"dateModified\":\"2022-03-09T10:22:36+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"width\":172,\"height\":174,\"caption\":\"Icon Newsroom_news\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dev.cometis.de\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/0f6ec71e9167dd48a24950f3cc6b2003\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"01. Juli 2019 | Dermapharm Holding SE with increased free float - cometis AG","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"01. Juli 2019 | Dermapharm Holding SE with increased free float - cometis AG","og_description":"Gr\u00fcnwald, July 1, 2019 \u2013 Dermapharm Holding SE (\"Dermapharm\"), a leading manufacturer of patent-free branded drugs for selected therapeutic areas in Germany with a growing international presence, has been informed by Themis Beteiligungs-Aktiengesellschaft (\"Themis\") that on June 28, 2019 580,000 shares of Dermapharm for the price of 30.00 Euros per share have been sold outside a trading venue.","og_url":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/","og_site_name":"cometis AG","article_published_time":"2019-07-01T15:08:14+00:00","article_modified_time":"2022-03-09T10:22:36+00:00","og_image":[{"width":172,"height":174,"url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#article","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/0f6ec71e9167dd48a24950f3cc6b2003"},"headline":"01. Juli 2019 | Dermapharm Holding SE with increased free float","datePublished":"2019-07-01T15:08:14+00:00","dateModified":"2022-03-09T10:22:36+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/"},"wordCount":387,"publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","keywords":["2019"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/","url":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/","name":"01. Juli 2019 | Dermapharm Holding SE with increased free float - cometis AG","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","datePublished":"2019-07-01T15:08:14+00:00","dateModified":"2022-03-09T10:22:36+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/01-juli-2019-dermapharm-holding-se-mit-erhoehtem-streubesitz\/#primaryimage","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","width":172,"height":174,"caption":"Icon Newsroom_news"},{"@type":"WebSite","@id":"https:\/\/dev.cometis.de\/de\/#website","url":"https:\/\/dev.cometis.de\/de\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.cometis.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dev.cometis.de\/de\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/dev.cometis.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/0f6ec71e9167dd48a24950f3cc6b2003","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/27090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/users\/24813"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=27090"}],"version-history":[{"count":0,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/27090\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media\/54374"}],"wp:attachment":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=27090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=27090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=27090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}